Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary

Ultragenyx Pharmaceutical

05/08/2025 22:01

Ultragenyx Pharmaceutical Inc RARE.OQ reported a quarterly adjusted loss of $1.17​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.52.  The mean expectation of nineteen analysts for the quarter was for a loss of $1.30 per share. Wall Street expected results to range from $-1.45 to $-1.04 per share.

Revenue rose 13.2% to $166.50 million from a year ago; analysts expected $161.59 million.

Ultragenyx Pharmaceutical Inc's reported EPS for the quarter was a loss of $1.17​.

The company reported a quarterly loss of $114.95 million.

Ultragenyx Pharmaceutical Inc shares had fallen by 21.7% this quarter and lost 32.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 3.4% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $81.00, about 64.9% above its last closing price of $28.46

This summary was machine generated from LSEG data August 5 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-1.30
-1.17
Beat
Mar. 31 2025
-1.61
-1.57
Beat
Dec. 31 2024
-1.29
-1.39
Missed
Sep. 30 2024
-1.45
-1.40
Beat